Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
EyePoint Pharmaceuticals Inc (DE:PV3B)
FRANKFURT:PV3B
RESEARCH TOOLSreports
Holding DE:PV3B?
Track your performance easily
PV3B Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€6.66 - €28.60
Previous Close€7.53
Volume0.00
Average Volume (3M)160.00
Market Cap
€484.08M
Enterprise Value€264.34M
Total Cash (Recent Filing)$253.79M
Total Debt (Recent Filing)$21.92M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Feb 27, 2025EPS Estimate
-€0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding68,251,031
10 Day Avg. Volume40
30 Day Avg. Volume160
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)2.35
Price to Sales (P/S)11.14
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.64
Enterprise Value/Gross Profit6.39
Enterprise Value/Ebitda-2.62
Forecast
1Y Price Target
€27.41Price Target Upside264.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EyePoint Pharmaceuticals News
PremiumCompany Announcements
EyePoint Pharmaceuticals Advances in Retinal Therapeutics
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe VERONA trial showed positive interim data with DURAVYU demonstrating an early and sustained improvement in visual acuity and macular thickness in diabetic macular edema patients.
Drug DevelopmentThe first patient was dosed in the pivotal LUCIA trial of DURAVYU in wet AMD, signaling progress in the development of a promising treatment.
Market PotentialDuravyu's potential 2X/year regimen represents a meaningful treatment burden reduction compared to Eylea and emerging Eylea-HD, which could garner a material share of the wAMD market despite entrenched competition.
Bears Say
Clinical TrialsRisks include the possibility of EYP-1901 failing in clinical trials or not obtaining regulatory approval.
CompetitionThe path forward for CLS-AX is seen as potentially challenging both clinically and commercially, reinforcing the competitive edge for EYPT.
ValuationPotential dilution risk is a concern for the valuation of the company.
---
PV3B FAQ
What was EyePoint Pharmaceuticals Inc’s price range in the past 12 months?
EyePoint Pharmaceuticals Inc lowest stock price was €6.66 and its highest was €28.60 in the past 12 months.
What is EyePoint Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is EyePoint Pharmaceuticals Inc’s upcoming earnings report date?
EyePoint Pharmaceuticals Inc’s upcoming earnings report date is Feb 27, 2025 which is in 56 days.
How were EyePoint Pharmaceuticals Inc’s earnings last quarter?
EyePoint Pharmaceuticals Inc released its earnings results on Nov 07, 2024. The company reported -€0.512 earnings per share for the quarter, beating the consensus estimate of -€0.517 by €0.006.
Is EyePoint Pharmaceuticals Inc overvalued?
According to Wall Street analysts EyePoint Pharmaceuticals Inc’s price is currently Undervalued.
Does EyePoint Pharmaceuticals Inc pay dividends?
EyePoint Pharmaceuticals Inc does not currently pay dividends.
What is EyePoint Pharmaceuticals Inc’s EPS estimate?
EyePoint Pharmaceuticals Inc’s EPS estimate is -€0.47.
How many shares outstanding does EyePoint Pharmaceuticals Inc have?
EyePoint Pharmaceuticals Inc has 68,251,030 shares outstanding.
What happened to EyePoint Pharmaceuticals Inc’s price movement after its last earnings report?
EyePoint Pharmaceuticals Inc reported an EPS of -€0.512 in its last earnings report, beating expectations of -€0.517. Following the earnings report the stock price went down -9.341%.
Which hedge fund is a major shareholder of EyePoint Pharmaceuticals Inc?
Among the largest hedge funds holding EyePoint Pharmaceuticals Inc’s share is Perceptive Advisors LLC. It holds EyePoint Pharmaceuticals Inc’s shares valued at 8M.
---
EyePoint Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€27.41 (264.11% Upside)
€27.41 (264.11% Upside)
Blogger Sentiment
Bullish
DE:PV3B Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.59%
12-Months-Change
Fundamentals
Return on Equity
-74.68%
Trailing 12-Months
Asset Growth
88.02%
Trailing 12-Months
Company Description
EyePoint Pharmaceuticals Inc
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
---
PV3B Earnings Call
Q4 2024
0:00 / 0:00
---
PV3B Stock 12 Month Forecast
Average Price Target
€27.41
▲(264.11% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Outlook Therapeutics
―
Ocular Therapeutix
―
Kala Pharmaceuticals
―
Best Analysts Covering PV3B
1 Year
1 Year Success Rate
9/23 ratings generated profit
1 Year Average Return
+50.69%
reiterated a buy rating 29 days ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 39.13% of your transactions generating a profit, with an average return of +50.69% per trade.
---